M&A Deal Summary |
|
|---|---|
| Date | 2015-12-02 |
| Target | DARA BioSciences |
| Sector | Life Science |
| Buyer(s) | Midatech Pharma |
| Deal Type | Merger |
| Advisor(s) | Aquilo Partners (Financial) K&L Gates (Legal) |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 2000 |
| Sector | Life Science |
| Employees | 18 |
| Revenue | 8M GBP (2017) |
Midatech is a nanomedicine company focused on the development and commercialisation of multiple, high-value, targeted therapies for major diseases with unmet medical need. Midatech Pharma was founded in 2000 and is based in Cardiff, the United Kingdom.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 3 |
| Sector: Life Science M&A | 2 of 2 |
| Type: Merger M&A Deals | 1 of 1 |
| State: North Carolina M&A | 1 of 1 |
| Country: United States M&A | 1 of 2 |
| Year: 2015 M&A | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-12-08 |
Q Chip
Cardiff, United Kingdom Q Chip has developed a complementary technology and products that allow sustained release of substances over extended periods of time and will provide a platform to incorporate Midatech’s gold nanoparticle (GNP) compounds for sustained and extended release. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2015-12-30 |
Galena Biopharma - Zuplenz
United States Galena Biopharma - Zuplenz® (ondansetron) Oral Soluble Film, is approved by the U.S. Food and Drug Administration for use in adult patients for the prevention of highly and moderately emetogenic chemotherapy-induced nausea and vomiting (CINV), radiotherapy-induced nausea and vomiting (RINV), and post-operative nausea and vomiting (PONV) |
Buy | - |
